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Kinase inhibitors represent the backbone of targeted
cancer therapy, yet only a limited number of onco-
genic drivers are directly druggable. By interrogating
the activity of 1,505 kinase inhibitors, we found
that BRD4-NUT-rearranged NUT midline carcinoma
(NMC) cells are specifically killed by CDK9 inhibition
(CDK9i) and depend on CDK9 and Cyclin-T1 expres-
sion. We show that CDK9i leads to robust induction
of apoptosis and of markers of DNA damage
response in NMC cells. While both CDK9i and bro-
modomain inhibition over time result in reduced
Myc protein expression, only bromodomain inhibi-
tion induces cell differentiation and a p21-induced
cell-cycle arrest in these cells. Finally, RNA-seq and
ChIP-based analyses reveal a BRD4-NUT-specific
CDK9i-induced perturbation of transcriptional elon-
gation. Thus, our data provide a mechanistic basis
for the genotype-dependent vulnerability of NMC
cells to CDK9i that may be of relevance for the devel-
opment of targeted therapies for NMC patients.
INTRODUCTION
Systematic genomic profiling of tumors, combined with the
development of targeted therapeutics, paved the way for a num-Cell Repo
This is an open access article under the CC BY-Nber of breakthroughs in the treatment of cancer patients (Buett-
ner et al., 2013; Clinical Lung Cancer Genome Project (CLCGP)
Network Genomic Medicine (NGM), 2013; Hyman et al., 2015;
Kandoth et al., 2013). In genetically defined subgroups such as
EGFR-mutant lung cancer the therapeutic exploitation of these
alterations has already led to dramatic improvements in the clin-
ical care of cancer patients (Flaherty et al., 2012; Rosell et al.,
2012; Shaw et al., 2013; Van Cutsem et al., 2011). However,
most oncogenic driver lesions are still considered to be
undruggable.
Massively parallel interrogation of drug vulnerability across
large panels of cancer cell lines has proved to be a valid tool
for the identification and validation of genetically defined targets
(Barretina et al., 2012; Garnett et al., 2012; Iorio et al., 2016; Mar-
tins et al., 2015; Seashore-Ludlow et al., 2015; Sos et al., 2009a,
2009b). Such screens can identify compounds that directly
target driver alterations and offer the opportunity to discover
additional vulnerabilities in non-mutated genes that only become
essential in tumor-specific genetic backgrounds (Chan et al.,
2011; Fece de la Cruz et al., 2015). Exploitation of such syn-
thetic lethality has already provided alternative therapeutic ap-
proaches to selectively kill cancer cells while sparing normal tis-
sue (McLornan et al., 2014). The cyclin-dependent kinases
(CDKs) 1, 2, and 6 have been shown to gain relevance in several
MYC-driven tumors and were thus proposed as context-specific
synthetic lethal targets (Fece de la Cruz et al., 2015). Moreover,
CDK9, which, together with Cyclin-T1, forms the positive tran-
scription elongation factor b (P-TEFb) complex and induces tran-
scriptional activation by hyperphosphorylating RNA polymeraserts 20, 2833–2845, September 19, 2017 ª 2017 The Authors. 2833
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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II (Pol II) (Lu et al., 2015; Morales and Giordano, 2016), was put
forth as a potential therapeutic target in hepatocellular carci-
noma (Huang et al., 2014), ovarian cancer (Lam et al., 2014),
and hematological malignancies (Gregory et al., 2015; Walsby
et al., 2014). As a consequence, several CDK inhibitors have
entered clinical trials, but so far, a lack of specificity and resulting
toxicity limits the clinical relevance of CDK inhibitors in cancer
(Chen et al., 2014; Kumar et al., 2015; Morales and Giordano,
2016).
Here we evaluated the cellular activity of a library of 1,505 ki-
nase inhibitors to systematically uncover genotype-specific vul-
nerabilities. Our data reveal that CDK9 inhibition specifically
modulates transcriptional elongation and effectively impairs
viability through induction of apoptosis and DNA damage
response of NUT midline carcinoma (NMC) cells.
RESULTS
High-Throughput Cell Line Screening
In total, 1,505 chemical compounds with a spectrum of common
kinase inhibitor motifs were screened against 78 cancer cell lines
(Figures 1A–1C) (Barretina et al., 2012; Garnett et al., 2012;
Sos et al., 2009b). Overall, 7.5% of all compound-cell line
combinations were classified as candidate hits (Z score < 2,
corresponding to a residual viability of <25.9% at 10 mM) (Fig-
ure S1A). The high number of compounds that elicited only low
or no cytotoxic effects across the cell lines is likely attributed
to most compounds not having undergone previous target-
based chemical or lead optimization (Figure 1A; Figure S1A).
Based on the number of hits across cell lines (nhits), compounds
showed a range of activity patterns ranging from lack of activity
(65.2% of all compounds, termed inactive; nhits < 2) to broad and
unselective toxicity (9.0%, termed toxic; nhits > 30% of cell lines)
(Figure 1A).
To assess the impact of chemical complexity on compound
activity, we calculated extended connectivity fingerprints
(ECFP6) (Riniker and Landrum, 2013), whose lengths correspond
to the number of distinct chemical features present in a given
molecule. Neither biological selectivity nor compound potency
depended on chemical complexity, as determined by the
ECFP6-fingerprint length (Figure 1B). Inactive, selective, and
toxic compounds were distributed at similar frequencies along
the fingerprint lengths (Figure 1B, upper panel). However, ana-
lyses of compounds grouped by basic chemical scaffold (HuFigure 1. High-Throughput Cell Line Screening
(A) Unsupervised hierarchical clustering of cell lines (columns, n = 78) and comp
represents classification of compounds based on the number of hits across cell lin
line panel.
(B) Top: density plot of inactive, selective, and toxic compounds along the ECFP6-
defined by the number of hits across cell lines, with chemical complexity assess
(C) Bar graph: distribution of the most frequent scaffolds in the compound library
(D) Volcano plot with viability reduction (x axis) and significance (y axis) of selec
discovery rate in the ANOVA model; *H1975 was not included as EGFRmut due t
(E) Schematic of the model building for elastic net models predicting percentage
(F) Correlation coefficients of predicted versus observed or randomly permutate
thiazoles (two-sided Mann-Whitney test).
(G) Classification of validation set compounds independent of underlying scaffold
inset; p value, Mann-Whitney test between compounds predicted to have high vand Bajorath, 2013) indicated that the number of active com-
pounds varied by core structures (Figure 1C). Specifically, com-
pounds with selective patterns of activity were typically based
on common scaffolds of established kinase inhibitors (e.g.,
amino-pyrimidines, imidazoles, indoles, pyrazoles, pyridines,
quinazolines, and thiazoles) (Figure 1C, boxplot). By contrast,
compounds based on a pyrazolopyrimidinone scaffold or those
with a highly complex core structure (mainly staurosporine and
derivatives thereof) were enriched in the group of primarily toxic
activity (Figure 1C). Thus, within our dataset core, scaffolds are a
major determinant of compound selectivity.
To discover genotype-specific effects of the selective com-
pounds, cell lines were grouped according to the presence or
absence of a given genomic alteration, and differences in the
viability in those cell lines bearing such alteration and in those
lacking it were tested by an ANOVA approach (Barretina et al.,
2012; Garnett et al., 2012; Iorio et al., 2016; Sos et al., 2009b).
Of all 6,664 possible compound-genotype combinations, 345
(hit rate = 5.2%) showed a significantly decreased viability in
altered versus wild-type cell lines (false discovery rate [FDR]%
0.1) with a significant enrichment of EGFR inhibitors scoring in
EGFR-mutant cell lines (Figure 1D).
We hypothesized that based on the structural diversity of in-
hibitors with differential activity against EGFR, we might also
be able to predict compound activity by chemical structure
alone. To this end, we applied elastic net modeling for regression
and classification of activity based on ECFP6 fingerprints using
a training subset (90% of compounds), coupled with 10-fold
cross-validation and subsequent testing on the remaining 10%
of the compounds (Figure 1E) (Zou and Hastie, 2005). We
first predicted median residual viability of EGFR-mutant cells
as a continuous measure based on the fingerprints of com-
pounds containing thiazoles (n = 398) or quinazolines (n = 172).
Overall, a high degree of correlation between predicted and
observed median viability was achieved for thiazoles (median
Pearson r = 0.74; p = 2.8 3 1033) (Figure 1F; Figure S1B) and
quinazoline-based compounds (median Pearson r = 0.76; p =
2.2 3 1047) (Figures S1C and S1D). Similarly, when performing
binary predictions of compounds as having either high or low
anti-EGFR activity in the complete compound set, irrespective
of underlying scaffolds, compounds predicted to have high
anti-EGFR activity exhibited significantly lower residual viabilities
(p = 1.0 3 108; area under the curve [AUC] 0.88) (Figure 1G). In
an independent validation with data of the GlaxoSmithKlineounds (rows, n = 1505) based on residual viability (heatmap). Color bar (rows)
es. Bottom: annotation of known driver alterations and their frequency in the cell
fingerprint length (color code as in A). Bottom: association of compound activity
ed by the compounds’ fingerprint lengths.
. Boxplot: number of hits of active compounds grouped by chemical scaffold.
tive compounds (n = 392) in genotypes annotated in (A) (n = 17). (FDR, false
o its T790M resistance mutation.)
of viability or classifying compounds as active or inactive.
d residual viability in EGFRmut cell lines based on 100 elastic net models for
. Discriminatory capacity is indicated by the receiver operator analysis (ROC,
ersus low activity against EGFRmut cell lines; CI, 95% confidence interval).
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Protein Kinase Inhibitor Set (GSK PKIS) compounds, the elastic
net model also reliably predicted high versus low activity against
L858R-mutated EGFR (p = 1.9 3 1019; AUC 0.85; sensitivity
77.2%; specificity 81.9%) (Figure S1E).
Thus, our inhibitor screening data capture major genomic de-
pendencies and our elastic net-based algorithm for the system-
atic deconvolution of genotype-chemotype relationships may be
useful for the analysis of similar large-scale screening datasets.
NMC Cells Are Sensitive to CDK9 Inhibition
The second most abundant genotype-chemotype interaction
present in our dataset was identified for a BRD4-NUT-rear-
ranged cell line (HCC2429) (Figure 1D) (Yan et al., 2011), which
was among the cell lines with the highest degree of sensitivity
toward several compounds (Figure S1F). BRD4-NUT fusions
are a hallmark of NMC, a rare but highly aggressive tumor type
associated with poor response to standard chemotherapy
(French et al., 2003; Stathis et al., 2016). Among selective com-
pounds with strong activity against HCC2429 cells, we identified
LDC67, a known CDK9 inhibitor, as the most genotype-selective
inhibitor (Figure 2A) (Albert et al., 2014). The 10 most active com-
pounds shared structural features with LDC67 and known CDK
inhibitors (Figure S2A) (Albert et al., 2014; Morales andGiordano,
2016; Rossi et al., 2005), suggesting that these chemotypes may
be suited as a backbone for CDK inhibitors. To further validate
our findings, we determined half-maximal growth inhibitory
(GI50) values of LDC67 across 64 cell lines, including three
NMC cell lines (HCC2429, 143100, and 690100), and found
significantly (p = 1 3 104) higher activity in all BRD4-NUT-rear-
ranged cells compared to tumor cells lacking the rearrangement
(Figure 2B; Figure S2B). We also observed a similar activity pro-
file in the cases of the CDK inhibitor AT7519 (p = 5 3 104)
(Squires et al., 2009) and the bromodomain inhibitor JQ1 (p =
1.4 3 107), which was previously shown to be active in NMC
cells (Figures S2C and S2D) (Filippakopoulos et al., 2010). In
line with these observations, CDK9 inhibition led to significantly
reduced cell growth of BRD4-NUT-rearranged cells in clono-
genic assays (p = 9 3 107) (Figure 2C) and an induction of
apoptosis at 24 hr (p = 0.001) and 48 hr (p = 0.005). Similarly,
LDC67 treatment led to a significant increase in the sub-G1
fraction (control, 8.0%; LDC67, 57%; p = 0.047) in BRD4-NUT-
rearranged cells, but not in control cells (Figure S2E). We subse-
quently sought to determine potential mechanistic links between
CDK9i and apoptosis induction. Because CDK9i has been
described as conferring an apoptosis-primed state by repres-
sing anti-apoptotic Mcl-1 (Gregory et al., 2015; Huang et al.,
2014; Lemke et al., 2014), we analyzed Mcl-1 expression levels
under LDC67 treatment as a function of time. Mcl-1 protein
expression was almost abrogated in HCC2429 cells, but not in
A549 (KRASmut) cells (Figure 2E). In addition to interfering with
global transcription and altering the balance of pro- and anti-
apoptotic proteins, CDK9 was shown to be involved in the
DNA damage response (Yu et al., 2010; Zhang et al., 2013).
We therefore investigated the levels of gH2AX and phospho-
Chk2, surrogate markers of DNA damage (Yu et al., 2010), under
LDC67 treatment. We observed strong upregulation of gH2AX
and phospho-Chk2 in HCC2429, while such induction was
considerably lower in A549 cells (Figure 2E). In addition, we2836 Cell Reports 20, 2833–2845, September 19, 2017were able to confirm a significant increase of gH2AX-positive
HCC2429 cells (24 hr) by fluorescence-activated cell sorting
(FACS) analysis after co-staining for gH2AX and cleaved cas-
pase-3 (Figure 2F).
Overall, our data suggest that BRD4-NUT-rearranged NMC
cells may be particularly vulnerable to CDK9 inhibition.
BRD4-NUT-Driven Cells Display a Distinctive CDK9
Dependency
To test a specific dependency of NMC cells on CDK9 expression
that may explain the observed phenotype in CDK9i-treated cells,
we performed short hairpin RNA (shRNA)-mediated knockdown
of both components of P-TEFb, CDK9, and Cyclin-T1 (Figures
3A and 3B). Similar to CDK9 inhibition, we observed a significant
(p = 2 3 104) reduction in cellular viability of NMC cells
(HCC2429), but not of control cells (A549) (Figures 3A and 3B).
We next tested the effects of LDC67 in NMC and control cells
(A549 and HCC15) on phosphorylation of Pol II and observed a
dose-dependent decrease of Ser2 phosphorylation, irrespective
of theunderlyinggenotype (Figure3C).Previously, cellular efficacy
of CDK9 inhibitors has been linked with changes in the complex
formation of P-TEFb with its negative regulator HEXIM1 (Huang
et al., 2014; Itzen et al., 2014; Lu et al., 2015; Morales and Gior-
dano, 2016). Tomonitor suchdrug-inducedeffects,weperformed
immunoprecipitation assays of endogenous CDK9 in HCC2429
and A549 cells treated with LDC67. We observed a modest but
reproducible reduction of HEXIM1-bound CDK9 in both cell lines
(Figure 3D), with a more profound disruption of HEXIM1/CDK9
complexes in HCC2429 cells (72.6%) when compared to A549
cells (85.6%) after 4 hr LDC67 treatment (Figure 3D). We were
able to validate this CDK9 inhibitor-induced effect when overex-
pressing FLAG-CDK9 in HCC2429 cells with a HEXIM1/FLAG-
CDK9 ratio of 14.6% after LDC67 (4 hr) treatment (Figure S3A).
These data further highlight the relevance of CDK9 expression
in NMC and suggest that the effects achieved by LDC67 may be
attributable to direct inhibition of CDK9.
CDK9-Specific Effects in NMC Cells
Previous reports have implicated MYC expression as a relevant
downstream effector of BRD4-NUT-driven cells in the context of
BRD4 inhibitor treatment (Grayson et al., 2014; Sos et al.,
2009b). To test the relevance of MYC expression in BRD4-
NUT-rearranged cells, we performed shRNA-mediated MYC
knockdown and observed a significant (p = 8.13 105) reduction
of viability in HCC2429 cells that did not strongly differ (p = 0.1)
from that of A549 control cells (Figure S3B). When monitoring
Myc protein levels during drug treatment, bromodomain inhibi-
tion with JQ1 led to a constant decrease of Myc protein expres-
sion as expected (Figures 4A and 4B; Figure S3C). To our sur-
prise, we observed an initial moderate increase of Myc protein
levels and a subsequent reduction after 48 to 72 hr of LDC67
treatment in HCC2429 BRD4-NUT-rearranged cells, but not in
A549 control cells (Figures 4A and 4B; Figure S3C) (Lu et al.,
2015). We observed a similar reduction of Myc protein levels,
together with an increase in gH2AX and depletion of Mcl-1 in
the 143100 NMC cells but without the initial Myc increase, sug-
gesting that the effect on Myc expression may be cell line spe-
cific (Figure S3D). The overlapping effects on Myc expression
Figure 2. CDK9 Inhibition Exhibits Distinct Effects on BRD4-NUT-Rearranged NMC Cells
(A) Activity of selective compounds against BRD4-NUT-rearranged HCC2429 cells. To obtain the most genotype-selective inhibitor, the percentage of cell lines
that were not impacted below the hit threshold was calculated for the ten most potent compounds (inset).
(B) GI50 values from LDC67 dose-response curves (72 hr) across 64 cell lines.
(C) Clonogenic survival assays of HCC2429 and A549 of LDC67 treatment or DMSO control (mean ± SD; n = 3).
(D) Apoptosis measured by Annexin V flow cytometry in BRD4-NUT-rearranged and control cells following treatment with 10 mM LDC67 (mean ± SD; n = 3).
(E) Immunoblot of HCC2429 and A549 cells treated with LDC67 for the indicated periods.
(F) HCC2429 cells treated for 24 hr with 10 mM LDC67, 0.5 mM JQ1, or DMSO were co-stained for cleaved caspase-3 (CC3) and gH2AX and measured by flow
cytometry (mean ± SEM; n = 3; p values calculated by two-tailed t tests).
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Figure 3. Effects of CDK9 or Cyclin-T1 Perturbation in NMC Cells
(A and B) shRNA-based gene knockdown of CDK9 or Cyclin-T1 was performed in HCC2429 and A549 cells and effects on viability (A) and protein levels (B) were
assessed compared to controls (mean ± SEM; n = 3).
(C) LDC67 on-target activity assessed by reduction of RNA polymerase II (Pol II) phosphorylation at Ser2 after 24 hr.
(D) Immunoprecipitations (IPs) of endogenous CDK9 show reduced HEXIM1/CDK9 complex abundance after 4 hr LDC67 treatment (n = 3; two-tailed t test). IgG
was used as unspecific negative IP control.induced by JQ1 and LDC67 may partly explain the additive
effects observed for the combination of both compounds and
partial cross-resistance of JQ1-persistent HCC2429 clones
(GI50 = 11.62 mM JQ1P versus GI50 = 72 nM parental) (Figures
S3E–S3H).
We also observed that treatment with both inhibitors led to in-
duction of cleaved caspase-3 within 24–48 hr (Figure 4A). Using
a more quantitative approach, we noticed a significantly higher
fraction of apoptotic cells under LDC67 compared to JQ1 treat-
ment in flow cytometric analyses (LDC67 61% versus JQ1 31%;
p = 0.02) (Figure S3I). By contrast, only bromodomain inhibition,
not CDK9 inhibition, led to a dramatic induction of the p53 target
gene p21 and a block of S phase entry (Figures 4A–4E; Fig-
ure S3J). In parallel, in JQ1-treated, but not LDC67-treated,
HCC2429 cells, we observed disassembly of hyperacetylated/
p300-positive foci that may lead to restoration of p53 activity,
as described in previous reports (Figures 4F and 4G) (Huang
et al., 2014; Reynoird et al., 2010).
Thus, our data indicate that in contrast to bromodomain inhi-
bition, CDK9 inhibition does not lead to a cell-cycle arrest and2838 Cell Reports 20, 2833–2845, September 19, 2017that over time, both perturbations induce a similar reduction of
Myc expression.
CDK9 Inhibition Perturbs Defined Transcriptional
Programs in NMC Cells
To further investigate the signaling patterns induced by CDK9
inhibition, we performed transcriptome profiling (RNA seq-
uencing [RNA-seq]) in NMC cells. RNA-seq indicated that
LDC67 treatment induces an initial increase (8 hr), followed
by downregulation (48 hr) of transcripts involved in RNA
binding and translation, of ribosomal subunits in gene set
enrichment analyses (GSEAs) and included known surrogate
markers of P-TEFb complex activity, such as FOS (Figures
5A–5C; Figure S4A; Tables S1 and S2) (Lu et al., 2015; Stathis
et al., 2016; Yan et al., 2011). We were also able to confirm
that LDC67 and JQ1 treatment was associated with a pertur-
bation of cellular processes linked with Myc activity (Figure 5C;
Tables S3 and S4). The changes induced by LDC67 were most
prevalent in genes regulated by promoters with high affinity for
Myc (Figure S4B) (Lorenzin et al., 2016; P.J. O’Dwyer et al.,
Figure 4. Differential Effects of CDK9 and
BRD4 Inhibition on NMC Cells
(A and B) Effects of JQ1 and LDC67 treatment on
protein levels in HCC2429 were assessed by
immunoblotting (A) and Myc protein levels over
time were quantified and normalized to actin (B)
(mean ± SEM; n = 5).
(C and D) Immunofluorescence of p21 protein
expression in HCC2429 cells after 24 hr LDC67
(10 mM) or JQ1 (500 nM) treatment (C). For quan-
tification (D), in total, >100 cells were assessed per
condition (bars represent the percentage of p21-
positive cells ± 95% CI; p values were calculated
by chi-square tests).
(E) Cell-cycle distribution of cycling cells assessed
by flow cytometry of propidium iodine-stained
HCC2429 cells after 24 hr treatment with 10 mM
LDC67 or 500 nM JQ1.
(F and G) Representative immunofluorescence (IF)
images of HCC2429 cells stained for p300 foci
after 24 hr DMSO, JQ1 (500 nM), or LDC67 (10 mM)
(F). Number of foci per nucleus was quantified in
n = 3 experiments (G), with >250 cells per condition
(two-tailed Wilcoxon tests).2016, Cancer Res., abstract). As expected, the timing of
the transcriptional changes and the individual gene sets in
HCC2429 cells treated with the bromodomain inhibitor JQ1
strongly differed from those treated with the CDK9 inhibitor
LDC67 (Figure 5C; Figures S4A–S4D). We also observed a
robust enrichment of genes involved in cytoskeletal regulation
in JQ1-treated cells and a reduction of cell-cycle gene sets
(Figure 5C; Figure S4A; Tables S1 and S2), which may corre-
spond to the morphological changes induced by JQ1 (Fig-
ure S4E) (Alekseyenko et al., 2015; Filippakopoulos et al.,
2010; Grayson et al., 2014; Stathis et al., 2016).Cell ReportsTo validate our RNA-seq results and to
assess the impact of CDK9i on de novo
transcription, we performed qRT-PCR of
mature mRNA and of unspliced pre-
mRNA for a set of upregulated genes
(FOS, JUNB, and MYC) and downregu-
lated genes (FOXO6 and KLHL23) after
LDC67 treatment. We chose 18S rRNA
for qPCR normalization that remained
stable under inhibitor treatment while
RNA-seq normalizes expression relative
to the complete transcriptome. Overall,
the RNA-seq results validated well for
mature and pre-mRNA (Figures 5B and
5E). Increased pre-mRNA levels of FOS
and JUNB suggest that these genes are
actively transcribed despite CDK9i. How-
ever, the strong decrease of FOXO6 and
KLHL23 pre-mRNA indicates CDK9i-
mediated elongation defects and abroga-
tion of de novo transcription.MYCmRNA
did not increase but instead stayed
constant at 8 hr of LDC67 treatment,followed by a delayed reduction at 48 hr (Figure 5B). The
apparent difference to the RNA-seq results is most likely due
to the aforementioned differences in normalization. Furthermore,
MYC pre-mRNA levels were decreased after 8 and 48 hr of
LDC67 treatment (Figure 5B). As expected, bromodomain inhibi-
tion with JQ1 led to a constant decrease of MYC pre-mRNA,
mature mRNA, and protein expression (Figure 4A; Figures 5D
and 5E). Depletion of CDK9 or Cyclin-T1 in these cells led to a
similar reduction of premature and mature MYC mRNA corre-
sponding to the respective knockdown efficacies (Figure 5F;
Figure S4F).20, 2833–2845, September 19, 2017 2839
Figure 5. Transcriptional Dynamics after CDK9 Inhibition in NMC Cells
(A) Time course of RNA-seq log2 fold changes for all genes (gray lines) between LDC67-treated and control (cont.) HCC2429 cells. Two gene ontology (GO) gene
sets (yellow and green) andMYC and FOS (red) are indicated. Error bars represent median and 10% or 90% quantiles of all log2 fold changes at respective time
points.
(B) qRT-PCR (normalized to 18S rRNA) of selected genes following LDC67 (10 mM) or DMSO control (cont.) for mature mRNA (left) and for unspliced pre-mRNA
(right) (mean ± SD; n = 3).
(C) GO terms enriched in gene set enrichment analysis (GSEA, C5) of RNA-seq data from HCC2429 treated (48 hr) with JQ1 (gray) or LDC67 (blue) compared to
controls (x axis, normalized enrichment score; FDR-corrected q values < 0.1 are considered significant).
(D) Time course of RNA-seq log2 fold changes for all genes (gray lines) between JQ1-treated and control (cont.) HCC2429 cells. Color codes as in (A).
(E) qRT-PCR (normalized to 18S rRNA) of selected genes following JQ1 (500 nM) treatment for mature mRNA (left) and for unspliced pre-mRNA (right)
(mean ± SEM; n = 3).
(F) qRT-PCR time course of MYC mRNA normalized to 18S rRNA after CDK9 (black) or Cyclin-T1 (gray) knockdown compared to shGFP controls (mean ± SEM;
n = 3).Thus, CDK9 inhibition may lead to defined genotype-specific
transcriptional changes but may also interfere with MYC mRNA
stability and increase MYC translation rather than de novo
transcription.
CDK9 Inhibition Has a Major Effect on Transcriptional
Elongation in NMC Cells
We next sought to directly evaluate the effect of CDK9 inhibi-
tion on the process of transcriptional elongation. To this
end, we performed chromatin immunoprecipitation (ChIP) ex-
periments after short-term CDK9 inhibition and measured Pol
II occupancy for genes in which expression was increased
(MYC, FOS, JUNB, and SF3B4) or did not increase (FOXO6,
KLHL23, BRG1, and NPM1) relative to the global transcriptome2840 Cell Reports 20, 2833–2845, September 19, 2017in RNA-seq analyses after short-term CDK9 inhibition (Figures
6A–6C; Figure S5). When assessing Pol II distribution with an
antibody raised against the unphosphorylated C-terminal
domain (CTD), Pol II occupancy in the gene body (GB) remained
constant or was even increased in upregulated genes, while the
GB signal was decreased in the other genes (Figures 6A–6C;
Figure S5). The signal at the transcription start site (TSS) was
more variable.
Overall, this translated into decreased pausing indices (PIs, or
the ratio of TSS-bound Pol II to GB-bound Pol II) for the upregu-
lated genes and constant or increased PI for the other genes
(Figure 6D). These findings are compatible with higher transcrip-
tion rates in the upregulated genes and correspond to signifi-
cantly lower RNA expression of the genes with increased
Figure 6. Effects of CDK9 Inhibition on Pol II Occupancy
(A and B) ChIP qPCR with an antibody raised against the unphosphorylated CTD assessing Pol II occupancy (displayed as a percentage of input DNA) at the
transcription start site (TSS) and the gene body (GB) of FOS and FOXO6 in HCC2429 (A) and A549 (B) after 4 hr LDC67 (10 mM) treatment compared to DMSO
controls (mean ± SD, n = 3).
(C) Relative changes of unphosphorylated CTD Pol II signal at TSS and GB between LDC67 and control cells.
(D) Pausing index (Pol II at TSS to Pol II in GB) for the selected genes normalized to DMSO control (mean ± SEM; n = 3).
(E) Log2 fold changes in RNA-seq of HCC2429 cells treatedwith LDC67 (8 hr and 10 mM) for the genes used for ChIP experiments. The p value between geneswith
high versus low PI was calculated by a Welch t test.
(F) Proposed model of the differential effects of CDK9 and JQ1 inhibition in NMC cells.pausing (p = 0.01 for PI > 1 versus PI < 1) (Figure 6E) (Huang et al.,
2014; P.J. O’Dwyer et al., 2016, Cancer Res., abstract). By
contrast, A549 cells showed reduced Pol II occupancy in all
genes on the GB and at varying degrees at the TSS (Figures
6B and 6C; Figure S5).To further investigate CDK9i-induced Pol II distribution, we
performed ChIP analyses for Pol II p-Ser5 and Pol II p-Ser2,
which indicate poised Pol II and elongating Pol II, respectively.
As expected, the signal for p-Ser5 Pol II corresponded well
to the total CTD-Pol II across the TSS and GB (r = 0.98,Cell Reports 20, 2833–2845, September 19, 2017 2841
p < 1010). This substantiates the findings that LDC67 prevents
Pol II pause release and productive elongation at FOXO6 and
KLHL23, thereby causing transcriptional repression of these
genes (Figure S5). Surprisingly, we noticed a more pronounced
decrease of the p-Ser2 Pol II signal following CDK9i at the TSS
of FOS and JUNB than in the GB and higher p-Ser2 levels at
the TSS, rather than a predominance of p-Ser2 Pol II signals in
theGB (Figure S5). Even though this was unexpected, similar ob-
servations are known from other ChIP studies andmay be due to
the genes under study and the location of primers used in the
qPCR (Nojima et al., 2015; Odawara et al., 2011; Stock et al.,
2007; Zhang et al., 2016). However, the constant p-Ser2 levels
in the gene bodies of FOS and JUNB following LDC67 treatment,
as well as the increased pre-mRNA levels, indicate productive
elongation and ongoing transcription during CDK9i. Although
this might be due to incomplete block of P-TEFb activity or
release of P-TEFb from its inhibitory complex after short-time in-
hibitor treatment (Lu et al., 2015), it may be speculated that this
effect is potentially due to involvement of other CDKs (e.g.,
CDK12 and/or CDK13) that were shown to be capable of phos-
phorylating Ser2 of Pol II CTD (Bo¨sken et al., 2014; Greifenberg
et al., 2016).
Overall, differential effects were observed not only between
HCC2429 and A549 but also among the genes investigated in
HCC2429. Altogether, these data underline the distinctive role
of CDK9 for transcriptional control in NMC cells, which may be
linked with their specific vulnerability to CDK9 inhibition.
DISCUSSION
Systematic screening of genetically annotated cancer cell lines
has proved to be a suitable tool for the identification of genetic
vulnerabilities and potential therapeutic targets (Barretina et al.,
2012; Garnett et al., 2012; Iorio et al., 2016; Martins et al.,
2015; Seashore-Ludlow et al., 2015; Sos et al., 2009b, 2009a).
Our screening approach involving 1,505 kinase inhibitors
coupledwith a systematic deconvolution and prediction of geno-
type-chemotype relationships enabled a structure-based pre-
diction of biological activity in silico and may thus be of value
to focus future screening projects on the most promising candi-
date compounds.
To our surprise, one of the most striking genotype-specific
vulnerabilities in our screen was the exquisite activity of
LDC67, a known CDK9 inhibitor in NMC cells (Albert et al.,
2014). Our chemical genomics approach uncovered a role of
CDK9 as a non-oncogenic driver for tumorigenesis in BRD4-
NUT-dependent cells mediated by regulation of transcription
and Myc protein levels in NMC. CDK9 has also been identified
as a key regulator of transcriptional regulation in MYC-overex-
pressing hepatocellular carcinoma (Huang et al., 2014). How-
ever, the evident CDK9i-induced differences on the level of Pol
II-mediated transcriptional elongation observed in NMC and
hepatocellular carcinoma indicate that these processes may
by distinct for individual lineages.
NMC is a rare but highly aggressive tumor with a median sur-
vival of 6.7months for which no approved therapies exist (Stathis
et al., 2016). An initial report from a BET inhibitor phase I/II trial
(GSK525762 and NCT01587703) described partial responses2842 Cell Reports 20, 2833–2845, September 19, 2017in 2 of 10 NMC patients (P.J. O’Dwyer et al., 2016, Cancer
Res., abstract), while another preliminary analysis reported a
partial response in 3 of 4 NMC patients after BET inhibitor
OTX015/MK-8628 with relapse within a few months (Stathis
et al., 2016). Of 10 NMC cases treated with GSK525762, four pa-
tients responded with stable disease (P.J. O’Dwyer et al., 2016,
Cancer Res., abstract). This is in line with the previous observa-
tions and our results, indicating that BRD4 inhibition leads to
dissolution of hyperacetylated nuclear foci, release of p53 with
induction of p21, cell-cycle arrest, and differentiation (Figures
4, 5C, 5D, and 6F; Figure S4E) (Alekseyenko et al., 2015; Grayson
et al., 2014; Reynoird et al., 2010; Yan et al., 2011). By contrast,
our data reveal that CDK9i may lead to robust Mcl-1 suppres-
sion, induction of DNA damage response and apoptosis in these
cells (Figure 6F). For several genes, including FOS, transcription
is increased following CDK9 inhibition. This has partly been
attributed to CDK9i-induced release of P-TEFb from its inhibitory
complex with HEXIM1 by a CDK9 inhibitor (Lu et al., 2015), an ef-
fect we also observed in NMC cells (Figure 3D and 6F; Fig-
ure S3A). We speculate that this phenomenon may be related
to structural changes of P-TEFb induced by CDK9 inhibitor bind-
ing (Baumli et al., 2008). AlthoughCDK9i-induced perturbation of
MYC expression partially overlaps with the effects of bromodo-
main inhibition, it remains to be seen how much these effects
contribute to the overall cellular phenotype observed for these
types of inhibitors. Overall, our findings uncover major molecular
differences between the mode of action of bromodomain and
that of CDK9 inhibitors in NMC and suggest that CDK9 may be
an attractive drug target in NMC patients.
In the past, clinical studies investigating spectrum CDK inhib-
itors such as dinaciclib or flavopiridol reported high rates of side
effects and dose-limiting toxicities (Kumar et al., 2015; Morales
and Giordano, 2016), but more selective compounds such as ri-
bociclib (CDK4 and CDK6) demonstrated the feasibility of CDK
inhibition even as first-line cancer treatment (Hortobagyi et al.,
2016). For this reason, several CDK9 inhibitors with improved
selectivity profiles were developed and hold promise for future
development in clinical applications (Albert et al., 2014; Lam
et al., 2014; Lu et al., 2015; Morales and Giordano, 2016). Our
findings may therefore be of relevance for the future develop-
ment of these drugs and the stratification of patients receiving
these types of selective CDK9 inhibitors.
In conclusion, our study provides a framework for the decon-
volution and prediction of genotype-chemotype relationships in
a large-scale kinase inhibitor screen and identifies CDK9 as a
druggable target in NMC. Our results also provide insight into
CDK9 exerted control of transcriptional elongation and its geno-
type-specific effects in BRD4-NUT-rearranged tumors.EXPERIMENTAL PROCEDURES
High-Throughput Screening
For high-throughput screening 78 genomically annotated patient-derived lung
cancer cell lines were assayed against 1,505 small-molecular compounds pre-
dominantly consisting of compounds before lead or target-based optimization
across a range of chemical scaffolds and a number of established reference
kinase inhibitors. For screening, cell lines were treated at a single-dose con-
centration, which was determined during a preliminary screen. Residual
viability was assessed after 72 hr by CellTiter-Glo (CTG, Promega). Chemical
information was captured by simplified molecular input line entry specification
(SMILES) codes and by manual annotation of scaffolds (Figure S6). A number
of compounds and cell lines were screened in duplicate to assess reproduc-
ibility. Moreover, external validity was assessed in a subset of compounds
and cell lines by testing compound activity in dilution series to assess GI50 after
72 hr by CTG (Promega). Genotype-specific compound activity was assessed
using an ANOVA approach similar to previous studies (Barretina et al., 2012;
Garnett et al., 2012; Seashore-Ludlow et al., 2015), incorporating genotype
and histological subtype in a random effects model. Activity predictions
were done with elastic net regression models using ECFP6 fingerprints of
the compounds as the predictor and residual viability or compound activity
as the response. Models were trained on a subset of compounds with
10-fold cross-validation and were evaluated on the compounds not involved
in model building and on an external validation dataset (Elkins et al., 2016).
Apoptosis, Proliferation, and Survival Assays
Apoptosis was measured by flow cytometry following Annexin V and propi-
dium iodide staining on a FACSGallios FlowCytometer and the corresponding
Kaluza analysis software (Beckman Coulter, USA). Cell-cycle analyses were
performed by flow cytometry on methanol-fixed cells after propidium iodide
staining. For FACS analysis of cleaved caspase-3 (CC3) and gH2AX, cells
were treated for indicated times, harvested by trypsinization, and fixed in
80% methanol. Fixed cells were permeabilized and blocked with PBS/1%
BSA before they were incubated with primary antibodies at 4C overnight.
The following day, cells were washed, incubated with Alexa Fluor secondary
antibodies (Thermo Scientific), and measured on a Gallios Flow Cytometer
(Beckman Coulter, USA).
For clonogenic survival assays, cells were seeded in 6-well plates, treated
for indicated times, fixed with 4% formaldehyde, and stained with crystal violet
solution. For quantification, a 1% SDS solution was added to the wells for
30 min and absorption was measured at 590 nm in the supernatant.
Immunoblot, Immunoprecipitation, and Immunofluorescence
Assays
Cellular signaling following LDC67 or JQ1 treatment was assessed by protein
gel electrophoresis. Equal amounts of protein lysates were separated on
4%–20% Novex Tris-glycine gels (Invitrogen), transferred to polyvinylidene
fluoride (PVDF) membrane, and incubated with indicated primary antibodies.
Proteins were detected with the Odyssey CLx imaging system (LI-CORBiosci-
ences). For immunoprecipitation, antibodies directed against endogenous
CDK9 or transiently transfected FLAG-CDK9 were used for precipitation at
4C overnight, followed by immunoblotting. FLAG-CDK9 plasmids were a
gift of Prof. Qiang Zhou (University of California, Berkeley, USA) (Lu et al.,
2015) and were transiently transfected before immunoprecipitation.
For immunofluorescence, cells were grown on coverslips and treated for
24 hr before fixation with 4% formaldehyde, followed by staining with the indi-
cated primary antibodies at 4Covernight. Samples were incubated with Alexa
Fluor secondary antibodies (Thermo Scientific) for 2 hr andmounted with DAPI
before imaging (Zeiss Meta 510 or Zeiss Meta 710).
shRNA Knockdowns
For knockdowns, respective shRNAs or shRNA against GFP (shGFP) were
generated with pLKO.1-puro vectors. Replication-deficient lentiviruses were
produced in HEK293T cells by co-transfection of pLKO.1-puro vectors and
helper plasmids. Supernatant collected 48 hr after transfection of HEK293T
cells was used to transfect HCC2429 and A549 cells. Knockdown efficiency
and effects on cell viability were validated by immunoblotting and CTG (Prom-
ega) 4–6 days after transfection, as described previously (Sos et al., 2009a).
ChIP
For ChIP experiments, cells were cross-linked with formaldehyde before chro-
matin was extracted, sonicated, and incubated with primary antibodies (Pol II,
pSer2-Pol II or pSer5-Pol II) or mouse immunoglobulin G (IgG) overnight. Anti-
body complexes were then captured with protein G beads, and DNA was
eluted, decrosslinked, and purified. ChIP signals were calculated by qPCR
(Table S5) relative to input levels after (IgG) background subtraction.RNA Analysis
For RNA-seq and qPCR (Table S5) analyses, total RNA was isolated following
LDC67 or JQ1 treatment. 30 RNA-seq libraries were prepared with the Quant-
Seq FWD 30 mRNA-Seq Kit (Lexogen, Austria), sequenced on an Illumina Hi-
Seq 4000, and quantified after alignment to the human genome reference
hg38. Data processing and statistical analyses were performed using Micro-
soft Excel (Microsoft, USA), GraphPad (Prism, USA), and R (R Development
Core Team, 2011). Half-maximal growth inhibitory (GI50) concentrations of
cell viability were inferred by fitting sigmoidal dose-response curves. Data
are represented as mean ± SEM, and significance was calculated by unpaired
Student’s t tests or Mann-Whitney tests unless indicated otherwise. The p
values are always two-sided. For details, see Supplemental Information.
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